117 Avenue de Luminy—BP 30191 13009 Marseille, France | VIA EDGAR |
October 11, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Donald Field |
Dietrich King
Keira Nakada
Lisa Vanjoske
| Re: | Innate Pharma S.A. |
Registration Statement on FormF-1
FileNo. 333-233865
Acceleration Request
Requested Date: October 16, 2019
Requested Time: 4:30 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement onForm F-1 to become effective on October 16, 2019, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Richard Segal, Brandon Fenn and Katie Kazem of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Richard Segal of Cooley LLP at +1 617 937 2332, or in his absence, Brandon Fenn at +1 212 479 6626. Thank you for your assistance with this matter.
[Signature Page Follows]
Sincerely,
Innate Pharma S.A. | ||||
| By: | /s/ Mondher Mahjoubi | |||
Mondher Mahjoubi Chief Executive Officer | ||||
| cc: | Richard Segal, Cooley LLP |
Yvan-Claude Pierre, Cooley LLP
Divakar Gupta, Cooley LLP
Brandon Fenn, Cooley LLP
Bertrand Sénéchal, Linklaters LLP
Deanna L. Kirkpatrick, Davis Polk & Wardwell LLP
Yasin Keshvargar, Davis Polk & Wardell LLP
Arnaud Duhamel, Gide Loyrette Nouel A.A.R.P.I.
Théophile Strebelle, Gide Loyrette Nouel A.A.R.P.I.